Smith & Nephew plc vs Williams-Sonoma, Inc. — how do they compare? Smith & Nephew plc trades at $27.21 (market cap $11.10B), while Williams-Sonoma, Inc. trades at $241.16 (market cap $28.15B). The key difference: Williams-Sonoma, Inc. is far larger — about 2.5× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 121 Days and Williams-Sonoma, Inc. for 59 Days on average.
| SNN | WSM | |
|---|---|---|
Market Cap | $11.10B | $28.15B |
Volume | 1,051,703 | 1,351,262 |
Sector | Health | Consumer Cyclical |
52-Week High | $37.17 | $251.81 |
52-Week Low | $26.42 | $168.64 |
Typical Hold Time | 121 Days | 59 Days |
Enterprise Value | $14.13B | $28.65B |
Dividend Yield | 2.95% | 1.27% |
Signals from Pluang's Aura AI — not financial advice
Smith+Nephew (SNN) trades at $27.24, near its 52-week low of $27.05, with a bearish technical signal despite recent earnings beats. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%, but the stock faces headwinds from analyst downgrades and CFO departure news. Product launches like the EVOS PELVIC System highlight innovation, yet investor sentiment remains cautious.
The outlook is mixed: strong fundamentals and undervaluation (P/E 18.34) offer upside, but technical weakness and competitive risks temper near-term gains. Key risks include execution challenges and market volatility, while institutional interest (e.g., BlackRock's $505M stake) provides support. Investors should weigh solid profitability against sentiment-driven price pressure.
Williams-Sonoma (WSM) trades at $241.75, up 0.54% on the day, with a bullish technical outlook and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.10 surpassing the $2.08 expectation. Revenue for 2025 was $7.71 billion, with a robust net income margin of 14.73% and high ROE of 54.96%. Recent news highlights market share gains and profitability improvements, including a new Pottery Barn collaboration and store expansion.
The outlook for WSM is positive, driven by earnings momentum, margin strength, and strategic initiatives. However, risks include competitive pressures in home furnishings and sensitivity to housing market trends. Analyst consensus is a buy with a $246.31 price target, suggesting modest upside from current levels, supported by institutional confidence and dividend declarations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →